Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gum disease study targets immune pathway for future treatments

NCT ID NCT07536204

Knowledge-focused Sponsor: University of Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study at the University of Chile is examining whether a specific immune pathway (JAK1/2) is overactive in people with periodontitis, a common gum disease. Researchers will compare gum tissue from 30 healthy adults and those with inflamed gums to measure pathway activation. The goal is to understand the disease better and identify potential targets for new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study shows the JAK1/2 pathway is overactive in periodontitis, it could point toward new drug targets for treating gum disease.
What could go wrong
This is a small, early observational study (30 participants) that only looks at tissue samples. It does not test any treatment, so any potential therapy is years away and may not work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults from the northern area of Santiago, Chile

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults * Sistemically healthy Exclusion Criteria: * Active Maliganancy * History of radiation to the head-neck region * Chemotherapy or radiation within the last 5 years * History of hepatitis B/C or HIV infection * Autoimmune diseases * Diagnosis of diabetes * Pregnancy or lactation * More than 3 hospitalizations over the last 3 years * Use of systemic antibiotics over the last 3 months * Use of systemic corticosteroids or immunosuppressants over the last 3 months * Use of cytokine therapy over the last 3 months * Use of large doses of pre/probiotic supplements over the last 3 months * Smoke more than 10 cigarettes per day

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gingival diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gingival disorder Inflammation Periodontal Attachment Loss periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gingival diseases Periodontal attachment loss Periodontal diseases Periodontal inflammation Periodontitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Dentistry, University of Chile

    RECRUITING

    Santiago, Metropolitan Region, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.